GlassScriptPhysician profile
Michael D Trotter
NPI 1992779599
$590,284.29
in general payments reported to CMS, 2019-2025
28 companies · $1,745 in 2025
The $1,745 reported for 2025 was more than what 77% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151K · 2020: $121K · 2021: $104K · 2022: $122K · 2023: $79K · 2024: $11K · 2025: $1,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $81K · Consulting Fee: $4,100 · Food and Beverage: $3,824 · Travel and Lodging: $2,703 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $81,018.75 |
| Consulting Fee | $4,100.00 |
| Food and Beverage | $3,824.42 |
| Travel and Lodging | $2,703.29 |
| Education | $165.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $319,760.67 | 2020-2025 | Urolift, Barrigel |
| Neotract INC. | $254,021.95 | 2019-2020 | |
| Olympus America INC. | $14,207.01 | 2022-2025 | Itind System |
| Boston Scientific Corporation | $876.89 | 2019-2025 | Spaceoar Vue System - 10ml, Rezum Generator, General - Oncology |
| Abbvie INC. | $283.20 | 2022-2025 | Botox |
| Astellas Pharma US INC | $186.78 | 2025 | Xtandi |
| Procept Biorobotics Corporation | $179.86 | 2019-2024 | Aquabeam System, Aquabeam Robotic System |
| Palette Life Sciences, INC. | $109.00 | 2022 | |
| Biotissue Holdings INC. | $71.42 | 2024 | |
| Ferring Pharmaceuticals INC. | $70.15 | 2025 | Adstiladrin |
| Axonics, INC. | $62.30 | 2023 | Axonics |
| Endo USA, INC. | $53.87 | 2025 | Aveed, Xiaflex |
| Biogen, INC. | $53.27 | 2019 | |
| Sumitomo Pharma America, INC. | $49.97 | 2024-2025 | Gemtesa |
| Accord Healthcare, INC. | $38.08 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $36.89 | 2019-2021 | |
| Antares Pharma, INC. | $28.37 | 2024-2025 | Xyosted |
| Telix Pharmaceuticals | $23.05 | 2024 | Illuccix |
| 180 Medical, INC. | $22.34 | 2019 | |
| Tolmar, INC. | $21.44 | 2023 | |
| Progenics Pharmaceuticals, INC. | $19.75 | 2025 | |
| Janssen Biotech, INC. | $17.51 | 2022 | |
| Myriad Genetic Laboratories, INC. | $16.76 | 2025 | Prolaris |
| Pfizer INC. | $16.68 | 2020 | |
| Mission Pharmacal Company | $15.64 | 2023 | Uribel |
| Stimwave Technologies Incorporated | $13.98 | 2021 | |
| Endo Pharmaceuticals INC. | $13.86 | 2019 | |
| Laborie Medical Technologies Corp. | $13.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Trotter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.